Investor Overview
Corporate Profile
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company with 20 years of mechanistic, translational, and clinical research across neurodegenerative diseases. We are building on breakthroughs in well-established biological pathways underlying neurodegeneration, to lead the charge in developing accessible, novel small-molecule therapies for age-related degenerative diseases that have historically received limited investment.
Zervimesine (CT1812), our investigational, first-in-class oral therapy, has a unique mechanism of action that displaces toxic protein oligomers from neuronal receptors. This approach to tackling neurodegeneration translates across indications in which toxic oligomers drive disease progression, offering potential treatment for dementia with Lewy bodies, Alzheimer’s disease, and Parkinson’s disease, among others.
